State-of-the-art staging in prostate cancer

BJU International

Volumn 87, Issue 5, 2001, Pages 423-430

  Wilkinson, B A ^a   Hamdy, F C ^a,b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TISSUE KALLIKREIN;

ARTIFICIAL INTELLIGENCE; CANCER DIAGNOSIS; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; IMMUNOSCINTIGRAPHY; LYMPHADENECTOMY; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; REVIEW; TECHNOLOGY; TRANSRECTAL ULTRASONOGRAPHY; TUMOR VOLUME;

BIOPSY; HUMANS; LYMPH NODE EXCISION; MAGNETIC RESONANCE IMAGING; MALE; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; NEOPLASM STAGING; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 0035075931     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2001.02146.x     Document Type: Review

References (55)

1. The natural history of prostate cancer based on a Danish population treated with no intent to cure
2. Early prostate cancer detection and potential for surgical cure in men with poorly differentiated tumours
3. The use of prostatic specific antigen, clinical stage and Gleason score to predict pathological stage in men with prostate cancer
4. Digital rectal examination for detecting prostate cancer at prostatic specific antigen levels of 4 ng/mL or less
5. Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European randomized study of screening for prostate cancer
6. Local staging of prostate cancer with transrectal ultrasound: A literature review
7. Comparison or magnetic resonance imaging and ultrasonography in staging early prostate cancer-results of a multi-institutional cooperative trial
8. Transrectal ultrasound versus digital rectal examination for the staging of carcinoma of the prostate: Results of a prospective multi-institutional trial
9. Transrectal ultrasound for staging prior to radical prostatectomy
10. Transrectal ultrasound for staging prostate carcinoma prior to radiation therapy
11. Prostate cancer staging: Correlation between ultrasound determined tumor contact length and pathologically confirmed extraprostatic extension
12. Staging of prostate cancer using 3-dimensional transrectal ultrasound images: A pilot study
13. Combination of prostatic specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer
14. Correlation of percent free PSA with pathologic features of prostatic carcinomas
15. The use of percent free prostatic-specific antigen for staging of men with clinically localised prostate cancer
16. The role of free/total prostatic-specific antigen ratio in the prediction of final pathological stage for men with clinically localised prostate cancer
17. Free, complexed and total serum prostate specific antigen concentrations and their proportions in predicting stage, grade, and deoxyribonucleic acid ploidy in patients with adenocarcinoma of the prostate
18. Percentage of free PSA in black versus white men for detection and staging of prostate cancer: A prospective multicenter clinical trial
19. Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer
20. Prostatic specific antigen density of the transition zone for predicting pathological stage of localised prostate cancer in patients with serum prostate specific antigen less than 10 ng/mL
21. Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ confined cancer compared with prostatic specific antigen
22. Human glandular kallikrein 2: A potential serum marker for predicting the organ confined versus non-organ confined growth of prostate cancer
23. The role of transrectal ultrasound-guided biopsy-based staging, preoperative serum prostate-specific antigen, and biopsy Gleason score in prediction of final pathological diagnosis in prostate cancer
24. Prediction of pathological stage and clinical outcome in prostate cancer: An improved pre-operative model incorporating biopsy-determined intraductal carcinoma
25. Extraprostatic biopsy improves the staging of localized prostate cancer
26. Seminal vesical biopsy: Accuracy and implications for staging of prostate cancer
27. The percentage of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy
28. The optimal systemic biopsy scheme should include 8 rather than 6 biopsies: Results of a prospective clinical trial
29. Carcinoma of the prostate gland: MR imaging with pelvic phased-array coils versus endorectal-pelvic phased-array coils
30. Prostate carcinoma: Assessment of diagnostic criteria for capsular penetration on endorectal coil MR images
31. Comparison of MR imaging and ultrasonography in staging early prostate cancer. Results of a multi-institutional co-operative trial
32. Prostate cancer: Prediction of extracapsular extension by endorectal MR imaging and 3D H-MR spectroscopic imaging
33. A comparison of endorectal resonance imaging and transrectal ultrasonography in the local staging of prostate cancer with histopathological correlation
34. An algorithm for predicting non-organ-confined prostate cancer using results obtained from sextant core biopsies with prostate specific antigen level
35. Introduction to neural networks
36. Novel staging tool for localized prostate cancer: A pilot study using genetic adaptive neural networks
37. The use of artificial intelligence technology to predict lymph node spread in men with clinically localised prostate carcinoma
38. The positive yield of imaging studies in the evaluation of men with newly diagnosed prostate cancer: A population based analysis
39. Lymph node staging of localized prostate carcinoma with CT and CT-guided fine-needle aspiration biopsy: Prospective study of 285 patients
40. Lymphangiography combined with biopsy and computer tomography to detect lymph node metastases in localised prostate cancer
41. Staging of prostate cancer with endorectal MRI. Lessons from a learning curve
42. Pelvic adenopathy in prostatic and urinary bladder carcinoma: MR imaging with a three-dimensional T1 weighted magnetization-prepared rapid gradient echo sequence
43. Characterization of reactive versus tumor-bearing lymph-nodes with interstitial magnetic imaging lymphography in an animal model
44. 111indium-labeled monoclonal antibody CYT-356
45. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18 fluorine-labeled deoxyglucose
46. 18fluorine-labelled deoxyglucose: Utility in localized and advanced prostate cancer
47. Eliminating the need for pelvic lymphadenectomy in select patients with prostate cancer
48. The staging pelvic lymphadenectomy: Implications as an adjunctive procedure for clinically localized prostate cancer
49. Mini-laparotomy pelvic lymph node dissection minimizes morbidity, hospitalization and cost of pelvic lymph node dissection
50. Which patients with prostatic carcinoma require a staging bone scan?
51. Molecular staging of prostate cancer with the use of enhanced reverse transcriptase-PCR assay
52. Combined nested RT-PCR assay for prostatic specific antigen and prostate specific membrane antigen in prostate cancer patients: Correlation with pathological stage
53. Bcl-2 over-expression combined with p53 protein accumulation correlates with hormone refractory prostate cancer
54. Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers
55. p53 protein accumulation and gene mutation in the progression of human prostatic carcinoma